ALS Centre Netherlands

UMC Utrecht

The ALS Centre Netherlands is the Dutch national centre of expertise on ALS.

Logo-UMC-Utrecht-2019_4
UMC Utrecht

We schedule all diagnostic research and consultations for each patient on one day. Around 90% of all Dutch ALS patients are diagnosed in our centre and over 500 patients are diagnosed each year. Prof. Leonard van den Berg, director of the ALS Centre Netherlands, is one of the initiators of the TRICALS platform with the aim to speed up the research for an ALS treatment by increasing collaboration between patients, industry and ALS centres. He is also one of the initiators of Project Mine (www.projectmine.com), which is the largest research effort worldwide to study the genetic basis of ALS. Additionally, our research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.

Contact
Location
Heidelberglaan 100, 3584 CX Utrecht, Nederland

Our team

Leonard van den Berg

Professor of Neurology and Chair of TRICALS

Leonard van den Berg is professor of neurology and chairman of TRICALS. […]

Leonard van den Berg
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more